

APAS® PHARMAQC DEMONSTRATED AT ASTRAZENECA UK SITE

Demonstration of APAS® PharmaQC during Pharmig Industry Event hosted by AstraZeneca

Adelaide, Australia, 22 February 2024: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in microbiology automation using artificial intelligence, is pleased to announce that the Company's APAS® technology was demonstrated to biopharmaceutical industry representatives at AstraZeneca's Macclesfield Campus in the United Kingdom. The demonstration featured as part of a tour of AstraZeneca's Quality Control (QC) microbiology laboratory during the 2-day Pharmig Modern Micro Methods industry event.

Highlights:

- AstraZeneca hosts APAS® PharmaQC showcase at Pharmig Modern Micro Methods 2-day industry event held at AstraZeneca's Macclesfield Campus in the United Kingdom
 - Onsite demonstrations of APAS® PharmaQC in AstraZeneca's QC microbiology laboratory
 - o AstraZeneca Presentation: Automated environmental monitoring plate reading powered by Al
- APAS® PharmaQC technology presented as best practice to biopharmaceutical industry innovators

The Pharmig Modern Micro Methods 2-day industry event was attended by over 40 pharmaceutical industry professionals seeking to learn about the latest technologies and best practice within pharmaceutical microbiology.

Delegates learned about the benefits of APAS® PharmaQC with a presentation by AstraZeneca, title "Automated environmental monitoring plate reading powered by Al". A tour of AstraZeneca's QC microbiology laboratory facilitated a hands-on demonstration and interaction with the APAS® instrument, providing a powerful real-world engagement with the technology. LBT's European sales executive was present and is conducting follow-up meetings with pharmaceutical industry professionals in attendance.

The presentation supports the Company's market development strategy for APAS® PharmaQC, building broader awareness of the technology within the market.

Brent Barnes, CEO & Managing Director said:

"AstraZeneca are setting the standard for the implementation of new technologies and considering improved ways of working within pharmaceutical microbiology. This 2-day event is a great way of sharing best practice with peers in industry and it is great to see our APAS® technology being included as a key part of the program."

About Pharmig

Pharmig is a leading industry body, based in the United Kingdom, that represents the interests of members who work in microbiology within the pharmaceutical, healthcare and cosmetics industries. It provides a forum for continuing professional development and serves as a unique network for the exchange of microbiological information through training courses, conferences and publications.

Approved for release by the Chair of the LBT Board.

- ENDS -



About LBT Innovations

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations

Brent Barnes

Chief Executive Officer & Managing Director

Tel: +61 8 8227 1555 E: info@lbtinnovations.com